AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-07-14 - Détachement de

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

167.2 USD

Average target price

183.2 USD

Spread / Average Target

+9.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+7.92%	295B
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B
PFIZER, INC.	-2.57%	159B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:21 2024-07-05 pm EDT			5-day change	1st Jan Change
167.2 ^USD	+2.08%		-2.49%	+7.92%

Jul. 05	Sector Update: Health Care Stocks Steady Premarket Friday	MT
Jul. 05	AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	MT

Sector Update: Health Care Stocks Steady Premarket Friday	Jul. 05	MT
AbbVie Flags Hit to Q2 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	Jul. 05	MT
AbbVie cuts 2024 profit forecast	Jul. 03	RE
Merus Names New Chief Medical Officer	Jul. 01	MT
AbbVie: new CEO takes up post	Jul. 01	CF
AbbVie Says Robert Michael Assumes CEO Role	Jul. 01	MT
AbbVie Announces Board Changes	Jul. 01	CI
AbbVie Inc.(NYSE:ABBV) added to Russell Top 200 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 3000 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 1000 Value-Defensive Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 1000 Value Index	Jun. 30	CI
AbbVie Inc.(NYSE:ABBV) added to Russell 3000E Value Index	Jun. 30	CI
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	Jun. 28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	Jun. 28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	Jun. 28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	Jun. 27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	Jun. 27	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	Jun. 27	MT
AbbVie: acquisition of Celsius for $250 million	Jun. 27	CF
AbbVie Buys Celsius Therapeutics for $250 Million	Jun. 27	DJ
AbbVie Buys Celsius Therapeutics for $250 million	Jun. 27	MT
AbbVie Buys Celsius Therapeutics for $250 million	Jun. 27	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	Jun. 27	MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	Jun. 27	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	Jun. 26	CI